| Name | Title | Contact Details |
|---|
Tricol Biomedical is dedicated to significantly advancing the standard of care in hemostatic and wound care management with a broad array of products.
Javan and Walter, Inc is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmacy OneSource is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. With a reputation for scientific and technical excellence, combined with a passion for delivering quality products on time, every time, our approximately 8,700 employees across North America, Europe, Latin America and Australia have enabled Patheon to achieve industry-leading growth. When you join Patheon, you are joining a team that is dedicated to transforming an industry and advancing our clients’ successes, today and tomorrow. Every day, our teams seek out opportunities for operational improvements across the enterprise to ensure we can deliver medicines that are right the first time and on time, while continually working to simplify the supply chain process and focus on what’s next by optimizing our offerings in innovative ways.
The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.